Infliximab Combined with Enteral Nutrition for Managing Crohn’s Disease Complicated with Intestinal Fistulas
Aim. This study was performed to evaluate the additional enteral nutrition (EN) in the efficacy of infliximab (IFX) compared with the conventional therapy in managing Crohn’s disease (CD) complicated with intestinal fistulas. Methods. A total of 42 CD with intestinal fistulas were randomly divided i...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2016/5947926 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545475838869504 |
|---|---|
| author | Xiao-Li Wu Ren-Pin Chen Li-Ping Tao Jian-Sheng Wu Xiang-Rong Chen Wei-Chang Chen |
| author_facet | Xiao-Li Wu Ren-Pin Chen Li-Ping Tao Jian-Sheng Wu Xiang-Rong Chen Wei-Chang Chen |
| author_sort | Xiao-Li Wu |
| collection | DOAJ |
| description | Aim. This study was performed to evaluate the additional enteral nutrition (EN) in the efficacy of infliximab (IFX) compared with the conventional therapy in managing Crohn’s disease (CD) complicated with intestinal fistulas. Methods. A total of 42 CD with intestinal fistulas were randomly divided into infliximab treatment group (n=20) and conventional therapy group (n=22). We evaluated the laboratory indexes, Crohn’s disease activity index (CDAI), Crohn’s disease simplified endoscopic score (SES-CD), and healing of fistula in the two groups before treatment, at 14 weeks, and at 30 weeks, respectively. Results. In the IFX treatment group, the CDAI score, the SES-CD, erythrocyte sedimentation rate, and C-reactive protein levels were significantly decreased during treatment compared with those before treatment. The body mass index and albumin levels were increased in both groups. Moreover, in the IFX treatment group, fistula healing was found in 8 at the 14th week and 18 at the 30th week, respectively, which was greater than that in the conventional therapy group. Conclusion. Our study suggested that infliximab combined with EN is an effective treatment for CD patients complicated with intestinal fistulas. |
| format | Article |
| id | doaj-art-daf70427683643ae97e347c77a41c8c5 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-daf70427683643ae97e347c77a41c8c52025-02-03T07:25:50ZengWileyGastroenterology Research and Practice1687-61211687-630X2016-01-01201610.1155/2016/59479265947926Infliximab Combined with Enteral Nutrition for Managing Crohn’s Disease Complicated with Intestinal FistulasXiao-Li Wu0Ren-Pin Chen1Li-Ping Tao2Jian-Sheng Wu3Xiang-Rong Chen4Wei-Chang Chen5Department of Gastroenterology, First Affiliated Hospital of Soochow University, Suzhou 215000, ChinaDepartment of Gastroenterology, First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang Province 325000, ChinaDepartment of Gastroenterology, First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang Province 325000, ChinaDepartment of Gastroenterology, First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang Province 325000, ChinaDepartment of Gastroenterology, First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang Province 325000, ChinaDepartment of Gastroenterology, First Affiliated Hospital of Soochow University, Suzhou 215000, ChinaAim. This study was performed to evaluate the additional enteral nutrition (EN) in the efficacy of infliximab (IFX) compared with the conventional therapy in managing Crohn’s disease (CD) complicated with intestinal fistulas. Methods. A total of 42 CD with intestinal fistulas were randomly divided into infliximab treatment group (n=20) and conventional therapy group (n=22). We evaluated the laboratory indexes, Crohn’s disease activity index (CDAI), Crohn’s disease simplified endoscopic score (SES-CD), and healing of fistula in the two groups before treatment, at 14 weeks, and at 30 weeks, respectively. Results. In the IFX treatment group, the CDAI score, the SES-CD, erythrocyte sedimentation rate, and C-reactive protein levels were significantly decreased during treatment compared with those before treatment. The body mass index and albumin levels were increased in both groups. Moreover, in the IFX treatment group, fistula healing was found in 8 at the 14th week and 18 at the 30th week, respectively, which was greater than that in the conventional therapy group. Conclusion. Our study suggested that infliximab combined with EN is an effective treatment for CD patients complicated with intestinal fistulas.http://dx.doi.org/10.1155/2016/5947926 |
| spellingShingle | Xiao-Li Wu Ren-Pin Chen Li-Ping Tao Jian-Sheng Wu Xiang-Rong Chen Wei-Chang Chen Infliximab Combined with Enteral Nutrition for Managing Crohn’s Disease Complicated with Intestinal Fistulas Gastroenterology Research and Practice |
| title | Infliximab Combined with Enteral Nutrition for Managing Crohn’s Disease Complicated with Intestinal Fistulas |
| title_full | Infliximab Combined with Enteral Nutrition for Managing Crohn’s Disease Complicated with Intestinal Fistulas |
| title_fullStr | Infliximab Combined with Enteral Nutrition for Managing Crohn’s Disease Complicated with Intestinal Fistulas |
| title_full_unstemmed | Infliximab Combined with Enteral Nutrition for Managing Crohn’s Disease Complicated with Intestinal Fistulas |
| title_short | Infliximab Combined with Enteral Nutrition for Managing Crohn’s Disease Complicated with Intestinal Fistulas |
| title_sort | infliximab combined with enteral nutrition for managing crohn s disease complicated with intestinal fistulas |
| url | http://dx.doi.org/10.1155/2016/5947926 |
| work_keys_str_mv | AT xiaoliwu infliximabcombinedwithenteralnutritionformanagingcrohnsdiseasecomplicatedwithintestinalfistulas AT renpinchen infliximabcombinedwithenteralnutritionformanagingcrohnsdiseasecomplicatedwithintestinalfistulas AT lipingtao infliximabcombinedwithenteralnutritionformanagingcrohnsdiseasecomplicatedwithintestinalfistulas AT jianshengwu infliximabcombinedwithenteralnutritionformanagingcrohnsdiseasecomplicatedwithintestinalfistulas AT xiangrongchen infliximabcombinedwithenteralnutritionformanagingcrohnsdiseasecomplicatedwithintestinalfistulas AT weichangchen infliximabcombinedwithenteralnutritionformanagingcrohnsdiseasecomplicatedwithintestinalfistulas |